Disc Medicine Inc. (IRON) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Disc Medicine Inc. (IRON)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

57.91

-0.83 (-1.41%)

At close: Jan 14, 2025, 3:59 PM

57.83

-0.14%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	45.87
Market Cap	1.72B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-3.95
PE Ratio (ttm)	-14.66
Forward PE	n/a
Analyst	Buy

Ask	59.8
Volume	268,432
Avg. Volume (20D)	320,200
Open	59.20
Previous Close	58.74
Day's Range	57.46 - 60.42
52-Week Range	25.60 - 77.60
Beta	undefined

About IRON

Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, M...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Aug 12, 2020

Employees 82

Stock Exchange NASDAQ

Ticker Symbol IRON

Website https://www.discmedicine.com

Analyst Forecast

According to 10 analyst ratings, the average rating for IRON stock is "Buy." The 12-month stock price forecast is $72.5, which is an increase of 25.19% from the latest price.

Buy 90.00%

Hold 10.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

2 months ago · Source

+11.21%

Disk Medicine shares are trading higher. HC Wainwr... Unlock content with Pro Subscription

2 months ago · Source

+23.59%

Disc Medicine shares are trading higher after the company announced the end of its Phase 2 Bitopertin In Erythropoietic Protoporphyria meeting with the FDA. The company is aligned with the FDA across all proposed study parameters and has a clear development path to registration.

News

7 months ago · seekingalpha.com

Disc Medicine: Hematological Disorders Treatment Advances With DISC-0974 Progress

Disc Medicine, Inc. released positive results from the phase 2 AURORA study, using bitopertin for the treatment of patients with EPP and XLP. Potential FDA feedback to initiate a pivotal study using b...

9 months ago · zacks.com

Disc Medicine (IRON) Down on Mixed Results From AURORA Study

Disc Medicine's (IRON) shares lose after a phase II study of bitopertin in patients with erythropoietic protoporphyria does not achieve the key secondary endpoint.

9 months ago · benzinga.com

Top 3 Health Care Stocks You'll Regret Missing This Month - Humana (NYSE:HUM), Disc Medicine (NASDAQ:IRON)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

9 months ago · investors.com

Disc Medicine Plummets 59% After Placebo Effect Confounds Sunlight Sensitivity Study

Disc's light sensitivity drug succeeded in a test Monday, but a large placebo response confounded the results. The biotech stock plummeted.

1 year ago · zacks.com

How Much Upside is Left in Disc Medicine, Inc. (IRON)? Wall Street Analysts Think 38.17%

The mean of analysts' price targets for Disc Medicine, Inc. (IRON) points to a 38.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement am...

1 year ago · investors.com

Stock Screen Finds These Growth Stocks Outperforming The S&P 500

This IBD stock screener identified three growth stocks with relative strength lines at new highs. One hit a 52-week high on Wednesday.

1 year ago · seekingalpha.com

Disc Medicine: Rare Disease Developer Derisking Itself

Disc Medicine is a developer of medicines for hematologic diseases with three clinical-stage candidates. IRON's lead candidate, bitopertin, is currently in phase 2 trials targeting erythropoietic porp...

1 year ago · zacks.com

Recent Price Trend in Disc Medicine, Inc. (IRON) is Your Friend, Here's Why

Disc Medicine, Inc. (IRON) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

1 year ago · investors.com

The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks

The top five biotech stocks today have several commonalities. Among them are strong ratings.

1 year ago · zacks.com

Here's Why Disc Medicine, Inc. (IRON) Is a Great 'Buy the Bottom' Stock Now

Disc Medicine, Inc. (IRON) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions coul...

1 year ago · seekingalpha.com

Disc Medicine: Soaring On EPP Data Release, Reality May Bite On Limited Market Opportunity

Disc Medicine stock has shown outstanding growth since the company joined the Nasdaq in December last year, gaining nearly 250%. The company released data today from a Phase 2 study of lead candidate ...

1 year ago · fool.com

Why Shares of Disc Medicine Opco Climbed This Week

Disc Medicine is a clinical-stage biopharmaceutical company specializing in treating blood disorders. The company's lead therapy, bitopertin, is in phase 2 trials to treat a rare inherited blood disor...

1 year ago · zacks.com

Disc Medicine, Inc. (IRON) is on the Move, Here's Why the Trend Could be Sustainable

Disc Medicine, Inc. (IRON) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it ...

2 years ago · investorplace.com

7 Short-Squeeze Stocks for Bold Contrarians to Consider

Throughout much of the new normal, the concept of short-squeeze stocks took off like wildfire. Essentially, this tactic centers on taking a contrarian bet against bearish traders in Wall Street's vers...

2 years ago · zacks.com

Gemini Therapeutics, Inc. (GMTX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Gemini Therapeutics, Inc. (GMTX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revision...